Revvity Inc

Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines. In 2022, a split of PerkinElmer resulted in one part, comprising its applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but keeping the PerkinElmer name. The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc. From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential. An associated goal was to have more financial flexibility moving forward. On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY.

RVTY

Financials

Revvity Inc

Notizie

RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data

What to Expect From Revvity's Next Quarterly Earnings Report

Revvity lancia una piattaforma software di clonazione molecolare basata su cloud

Stifel conferma Hold su Revvity con target di $110

Stifel reiterates Hold on Revvity stock, keeps $110 price target

Revvity alla Conferenza Barclays: Strategie per la Crescita

Revvity at Conference Barclays: Strategic Insights for Growth

Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Why Is Revvity (RVTY) Down 5.1% Since Last Earnings Report?

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

Revvity a TD Cowen: crescita strategica ed espansione dei margini

Revvity at TD Cowen: Strategic Growth and Margin Expansion